Article Text

other Versions

PDF
Extended report
A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever
  1. Fiona Moghaddas1,2,
  2. Rafael Llamas3,
  3. Dominic De Nardo1,2,
  4. Helios Martinez-Banaclocha4,
  5. Juan J Martinez-Garcia4,
  6. Pablo Mesa-del-Castillo4,5,
  7. Paul J Baker1,2,
  8. Vanessa Gargallo3,
  9. Anna Mensa-Vilaro6,
  10. Scott Canna7,
  11. Ian P Wicks1,2,8,
  12. Pablo Pelegrin4,
  13. Juan I Arostegui6,
  14. Seth L Masters1,2
  1. 1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
  2. 2Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
  3. 3Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain
  4. 4Inflammation and Experimental Surgery Unit, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
  5. 5Department of Rheumatology, Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
  6. 6Department of Immunology-CDB, Hospital Clinic-IDIBAPS, Barcelona, Spain
  7. 7Pediatric Rheumatology/RK Mellon Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA
  8. 8Department of Rheumatology, The Royal Melbourne Hospital, Parkville, Australia
  1. Correspondence to A/Prof Seth L Masters, Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; masters{at}wehi.edu.au

Abstract

Objective Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis (PAAND) is a recently described monogenic autoinflammatory disease. The causal p.S242R MEFV mutation disrupts a binding motif of the regulatory 14-3-3 proteins within pyrin. Here, we investigate a family with clinical features consistent with PAAND in whom the novel p.E244K MEFV mutation, located in the +2 site of the 14-3-3 binding motif in pyrin, has been found.

Methods Multiplex cytokine analyses were performed on p.E244K patient and control serum. Peripheral blood mononuclear cells were stimulated ex vivo with lipopolysaccharide (LPS). In vitro, inflammasome complex formation was evaluated by flow cytometry of Apoptosis-associated Speck-like protein containing a Caspase recruitment domain (ASC) specks. Interleukin-1β (IL-1β) and IL-18 production was quantified by ELISA. The ability of the p.E244K pyrin mutation to interact with 14-3-3 was assessed by immunoprecipitation.

Results PAAND p.E244K patient serum displayed a different cytokine profile compared with patients with Familial Mediterranean Fever (FMF). In overexpression models, p.E244K pyrin was associated with decreased 14-3-3 binding and increased ASC speck formation. THP-1 monocytes expressing PAAND pyrin mutations demonstrated spontaneous caspase-1-dependent IL-1β and IL-18 secretion, as well as cell death, which were significantly greater than those of wild-type and the FMF-associated mutation p.M694V.

Conclusion In PAAND, disruption of the +2 position of a 14-3-3 binding motif in pyrin results in its constitutive activation, with spontaneous production of IL-1β and IL-18, associated with inflammatory cell death. The altered serum cytokine profile may explain the different clinical features exhibited by PAAND patients compared with those with FMF.

  • pyrin
  • PAAND
  • autoinflammatory disease
  • 14-3-3
  • FMF

Statistics from Altmetric.com

Footnotes

  • Handling editor Tore K Kvien

  • Contributors FM, JIA, SLM: Conception and design of the work. FM, RL, DDN, HMB, JJMG, PMdeC, PJB, VG, AMV, SC, IPW, PP, JIA, SLM: Performed experiments, data collection, analysis and interpretation. All authors were involved in drafting and approval of the manuscript.

  • Funding IPW: Australian National Health andMedical Research Council Program (NHMRC) project grant (1113577). PP: Grants from Instituto Salud CarlosIII-FEDER (PS13/00174) and European Research Council (ERC-2013-CoG 614578). PP would like to acknowledge networking support by the COST Action BM-1406. HMB: Rio Hortega fellowship from Instituto Salud Carlos III (CM14/00008), JIA: CERCA Programme/Generalitat de Catalunya and SAF2015-68472-C2-1-R grant from the Spanish Ministry of Economy and Competitiveness and Fondo Europeo de Desarrollo Regional (FEDER). SLM: NHMRC projects grants (1099262, 1081299) Viertel Fellowship and funding from Glaxosmithkline.

  • Competing interests None declared.

  • Ethics approval Hospital Clinic-IDIBAPS Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.